SEC Comment Letter 0000000000-23-005173 to iTeos Therapeutics, Inc. (ITOS) (CIK 0001808865)
iTeos Therapeutics, Inc. (ITOS) (CIK 0001808865)
Date: May 15, 2023 · CIK: 0001808865 · Accession: 0000000000-23-005173
AI Filing Summary & Sentiment
File numbers found in text: 333-271793
Letter
United States securities and exchange commission logo May 15, 2023 Adi Osovsky Vice President, Legal iTeos Therapeutics, Inc. 321 Arsenal Street Watertown, Massachusetts 02472 Re:iTeos Therapeutics, Inc. Registration Statement on Form S-3 Filed May 10, 2023 File No. 333-271793 Dear Adi Osovsky: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
May 15, 2023
Adi Osovsky
Vice President, Legal
iTeos Therapeutics, Inc.
321 Arsenal Street
Watertown, Massachusetts 02472
Re:iTeos Therapeutics, Inc.
Registration Statement on Form S-3
Filed May 10, 2023
File No. 333-271793
Dear Adi Osovsky:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jimmy McNamara at 202-551-7349 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences